Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 422 0.02%
21 Nov - close price
akums.in BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 6,631 Cr.
  • Current Price ₹ 422
  • High / Low ₹ 706 / 405
  • Stock P/E 48.4
  • Book Value ₹ 151
  • Dividend Yield 0.00 %
  • ROCE 16.2 %
  • ROE 13.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 25.9% CAGR over last 5 years

Cons

  • Company has a low return on equity of 13.8% over last 3 years.
  • Earnings include an other income of Rs.122 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
316 447 383 298 317 328 337 329 332 309
503 358 351 359 274 285 303 311 288 292
Operating Profit -187 89 32 -61 44 43 34 18 44 17
OPM % -59% 20% 8% -20% 14% 13% 10% 5% 13% 5%
20 4 25 25 26 32 34 32 29 27
Interest 4 5 5 5 6 4 2 3 3 2
Depreciation 7 8 8 9 9 9 11 10 10 11
Profit before tax -178 81 43 -49 54 62 55 37 60 31
Tax % 6% 35% 32% 18% 23% 18% 25% 26% 25% 25%
-190 53 29 -58 42 50 41 28 45 23
EPS in Rs -13.26 3.69 2.05 -4.05 2.84 3.20 2.62 1.75 2.85 1.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
596 683 737 837 1,162 1,287 1,444 1,312 1,308
521 603 697 811 1,524 1,045 1,570 1,177 1,195
Operating Profit 75 80 40 27 -362 242 -126 135 113
OPM % 13% 12% 5% 3% -31% 19% -9% 10% 9%
55 58 66 -195 58 -48 74 128 122
Interest 3 4 4 1 4 13 18 15 10
Depreciation 23 23 25 26 28 30 33 40 42
Profit before tax 105 112 76 -195 -335 150 -103 208 183
Tax % 35% 33% 33% -26% 14% 17% 61% 23%
68 75 51 -145 -382 125 -165 161 137
EPS in Rs 576.34 636.94 391.05 -1,118.18 -53.37 8.77 -11.56 10.23 8.71
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 12%
3 Years: 4%
TTM: -1%
Compounded Profit Growth
10 Years: %
5 Years: 26%
3 Years: 34%
TTM: 112%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -34%
Return on Equity
10 Years: %
5 Years: -1%
3 Years: 14%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 1 1 1 1 14 29 29 31 31
Reserves 766 841 711 566 171 283 115 2,275 2,342
33 51 36 41 140 146 267 46 46
160 153 678 690 1,488 1,437 1,684 333 303
Total Liabilities 960 1,046 1,426 1,298 1,814 1,894 2,095 2,685 2,722
236 237 242 244 253 272 317 356 385
CWIP 0 0 1 1 1 16 9 57 44
Investments 4 4 65 149 141 139 139 366 366
720 806 1,118 903 1,419 1,466 1,631 1,906 1,926
Total Assets 960 1,046 1,426 1,298 1,814 1,894 2,095 2,685 2,722

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-22 56 228 94 248 91
-242 -100 -298 -202 -165 -459
302 3 95 90 -21 375
Net Cash Flow 38 -42 25 -18 62 8

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 74 85 88 92 95 73 59 57
Inventory Days 123 93 96 67 85 91 68 92
Days Payable 87 60 85 63 120 82 69 100
Cash Conversion Cycle 110 118 99 96 61 82 58 49
Working Capital Days 109 103 121 89 -2 4 -11 47
ROCE % 14% 10% 8% -71% 79% -15% 16%

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
75.26% 75.26% 75.26% 75.26% 75.26%
7.34% 6.36% 5.77% 4.24% 2.27%
7.53% 6.99% 7.39% 8.85% 9.28%
7.14% 8.64% 8.84% 8.92% 10.46%
2.73% 2.73% 2.73% 2.73% 2.73%
No. of Shareholders 57,53168,41069,36669,42475,365

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls